mRNA VLP Vaccine for COVID-19
(ARTEMIS-C Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing two new vaccines, AZD9838 and AZD6563, in healthy adults to see if they are safe and help the immune system fight COVID-19.
Do I need to stop my current medications to join the trial?
The trial information does not specify if you need to stop taking your current medications. However, it does mention restrictions on recent vaccinations and certain treatments like COVID-19 monoclonal antibodies. It's best to discuss your specific medications with the trial team.
Is the mRNA VLP Vaccine for COVID-19 safe for humans?
How is the mRNA VLP Vaccine for COVID-19 different from other COVID-19 treatments?
The mRNA VLP Vaccine for COVID-19 is unique because it uses virus-like particles (VLPs) that mimic the structure of the virus without containing its genetic material, making it safe and highly effective in triggering a strong immune response. This platform is flexible, allowing for easy updates to address new virus variants, and can be mass-produced and stored efficiently.12678
What data supports the effectiveness of the treatment AZD9838 in the mRNA VLP Vaccine for COVID-19 trial?
Virus-like particle (VLP) vaccines, like the one being studied, have shown to be effective in producing strong immune responses against COVID-19 by mimicking the virus structure without causing disease. Studies have demonstrated that VLP vaccines can induce high levels of neutralizing antibodies, which help block the virus from infecting cells, and have been effective in animal models.267910
Are You a Good Fit for This Trial?
Adults aged 18-64 with a BMI under 35, who've had COVID-19 or been vaccinated against it at least 6 months ago. They must test negative for SARS-CoV-2 and be medically stable. Pregnant women, recent vaccine recipients, those with certain allergies or heart issues, and individuals with immune conditions are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single intramuscular dose of either AZD9838, AZD6563, or a licensed mRNA vaccine
Follow-up
Participants are monitored for safety and immunogenicity, including antibody response and adverse events
What Are the Treatments Tested in This Trial?
Interventions
- AZD9838
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology